Detection of Minimal Residual Disease by Flow Cytometry for Patients with Multiple Myeloma Submitted to Autologous Hematopoietic Stem Cell Transplantation
The treatment strategy in multiple myeloma (MM) is to get complete remission followed by high-dose chemotherapy and autologous Hematopoietic Stem Cell Transplantation (HSCT). Neoplastic Plasma Cells (NPCs) are CD45−/dim, CD38+high, CD138+, CD19−, and CD56+high in most cases. The description of this...
Main Authors: | Dal Bó, Suzane, Pezzi, Annelise, Amorin, Bruna, Valim, Vanessa, Isabel Bittencourt, Rosane, Silla, Lucia |
---|---|
Format: | Online |
Language: | English |
Published: |
Hindawi Publishing Corporation
2013
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3705753/ |
Similar Items
-
Validation of the EBMT Risk Score for South Brazilian Patients
Submitted to Allogeneic Hematopoietic Stem Cell Transplantation
by: Pitombeira, Beatriz Stela, et al.
Published: (2013) -
DNMT3A Mutations in Patients with Acute Myeloid Leukemia in South Brazil
by: Pezzi, Annelise, et al.
Published: (2012) -
Erratum to “DNMT3A Mutations in Patients with Acute Myeloid Leukemia in South Brazil”
by: Pezzi, Annelise, et al.
Published: (2014) -
Mesenchymal stem cell therapy and acute graft-versus-host disease: a review
by: Amorin, Bruna, et al.
Published: (2014) -
Comparative analysis of minimal residual disease detection by multiparameter flow
cytometry and enhanced ASO RQ-PCR in multiple myeloma
by: Silvennoinen, R, et al.
Published: (2014)